Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus to Screen Schering-Plough Candidates

NEW YORK (GenomeWeb News) – Galapagos subsidiary BioFocus DPI will conduct drug discovery screening and targeting studies over a one-year period for Schering-Plough, Galapagos said today.

Under the €2.8 million ($4.1 million) agreement, BioFocus will perform medicinal chemistry and studies of absorption, distribution, excretion, and pharmacokinetics for multiple Schering-Plough projects at two sites in Europe.

The company said that the agreement with the Schering-Plough Research Institute builds on an earlier drug discovery project between the companies that was agreed upon in May of this year.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.